Tag Archive for: Covid-19

Point-of-Care (POC) Diagnostic Testing: 5 Key Trends to Watch from 2022-2026

Globally, millions of dollars are spent annually on point-of-care (POC) diagnostic testing, both professional testing (which includes physician office labs, clinic labs, employer labs and hospital labs) and self-testing (which includes home, drug store testing and continuous glucose testing).  In 2021, amidst the pandemic, the POC market reached $41,149 million ($41.1 billion) and the market […]

106 Billion IVD Procedures and Counting

“Medical market researcher Kalorama Information forecasts exponential growth in both in vitro diagnostics (IVD) procedures and sales between 2021 and 2026.”   The global in vitro diagnostics (IVD) procedures market continues to grow off momentum originating at the height of the pandemic and lingering on today. There are currently 106,624 million (106 billion) in vitro […]

COVID-19 and 6 Other Trends Impacting the In Vitro Diagnostics (IVD) Market

  “In many ways, the IVD testing market is center stage for the fight against the coronavirus…The COVID-19 market continues to play a major role in the growth of the IVD market with tests for the virus representing 27% of sales in 2021.” – Kalorama Information   Make no mistake, the in vitro diagnostics (IVD) […]

COVID-19 Testing Increases Demand in $150 Billion Clinical Laboratory Services Market, Future Growth Linked to Global Economies

  The global market for clinical laboratory services grew to an estimated $150.4 billion during 2020, with COVID-19 testing demand increasing the market by more than $26 billion over the year. These findings are according to insights featured in Clinical Laboratory Services Market, 6th Edition, a new report by leading medical market research publisher Kalorama […]

COVID-19 Testing Increases Value of Global Molecular Diagnostics Market

As the COVID-19 crisis surfaced in the United States, molecular diagnostic manufacturers went to work with new RT-PCR testing kits. The worldwide demand for COVID tests has materialized rapidly from zero and already on course become a 1.3 billion-dollar market in the first half of 2020.  There have been hundreds of tests on the market […]

Could COVID-19 Influence LDT Regulation?

Lab-developed tests were controversial before the COVID-19 pandemic, and there was attempts at regulating them more in the United States.  Then came a massive infectious disease threat for which lab developed tests were essential.  The sudden onset of a disease for which there were no existing test products, so labs had to develop their own. […]

As COVID Testing Expands Rapidly, Recommendations and Consenus Taking Shape

The landscape of COVID-19 testing has been rapidly evolving.  New products and services are continually being introduced, and regulatory approvals have been growing and expanding to include more types of tests, samples, and sample collection methods.  With the sudden global demand and governments loosening requirements during the crisis, there has been an unprecedented flood of […]

COVID-19 Has Small Negative Impact on Important Companion Diagnostic Testing, Report Finds

Companion diagnostics are rising to the forefront of pharmaceutical development and treatment. Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. The COVID-19 pandemic has gripped the world and continues to be a major area of research and development […]

Coagulation Tests Find Use in COVID-19, New Anticoagulants

Coagulation is a complex process in which multiple enzymes and proteins regulate blood flow and clot formation. Coagulation (clot formation), fibrinolysis and platelet aggregation are a part of this process. Fibrinolysis refers to the breakup of blood clots. It is a normal body process that keeps naturally occurring blood clots from growing and causing problems. Anticoagulant drugs help prevent blood platelets from sticking or clumping together, reducing the likelihood that arteries will be blocked by a clot, leading to a stroke or heart attack.

Drug Discovery Outsourcing – COVID-19 has Mixed Effect

Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the U.S. Food & Drug Administration (FDA) or other global regulatory agencies. The average drug can take 10+ years to progress from the discovery phase to the clinic, […]